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Abstract
Aerobic glycolysis supports proliferation through unresolved mechanisms. We have previously 
shown that aerobic glycolysis is required for the regulated proliferation of cerebellar granule 
neuron progenitors (CGNPs), and for the growth of CGNP-derived medulloblastoma. Blocking the 
initiation of glycolysis via deletion of Hexokinase-2 (Hk2) disrupts CGNP proliferation and 
restricts medulloblastoma growth. Here, we assessed whether disrupting Pyruvate kinase-M 
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(Pkm), an enzyme that acts in the terminal steps of glycolysis, would alter CGNP metabolism, 
proliferation and tumorigenesis. We observed a dichotomous pattern of PKM expression, in which 
post-mitotic neurons throughout the brain expressed the constitutively active PKM1 isoform, while 
neural progenitors and medulloblastomas exclusively expressed the less active PKM2. Isoform-
specific Pkm2 deletion in CGNPs blocked all Pkm expression. Pkm2-deleted CGNPs showed 
reduced lactate production and increased SHH-driven proliferation. 13C-flux analysis showed that 
Pkm2 deletion reduced the flow of glucose carbons into lactate and glutamate without markedly 
increasing glucose-to-ribose flux. Pkm2 deletion accelerated tumor formation in medulloblastoma-
prone ND2:SmoA1 mice, indicating the disrupting PKM releases CGNPs from a tumor-
suppressive effect. These findings show that distal and proximal disruptions of glycolysis have 
opposite effects on proliferation, and that efforts to block the oncogenic effect of aerobic 
glycolysis must target reactions upstream of PKM.
Introduction
Increased aerobic glycolysis, a common feature of proliferating cells during developmental 
and malignant growth (1,2), has been proposed as a target for anticancer therapy. CGNPs are 
transit amplifying cells that proliferate in the postnatal brain (3,4) that utilize aerobic 
glycolysis during normal brain development (5). CGNPs are also cells-of-origin for SHH-
subgroup medulloblastoma (6,7). Medulloblastomas co-opt developmentally-regulated 
programs of CGNPs (6,7), including the metabolic phenotype of increased aerobic 
glycolysis (5,8). Understanding how aerobic glycolysis supports CGNP proliferation and 
medulloblastoma tumorigenesis is essential for designing metabolically-directed 
medulloblastoma therapies.
During postnatal brain development, CGNPs proliferate in the cerebellum in response to 
locally secreted Sonic Hedgehog (SHH), generating the largest neuron population in the 
mammalian brain (9–11). In synchrony with increased CGNP proliferation, SHH signaling 
induces Hexokinase-2 (HK2) and aerobic glycolysis (5,8). Approximately 30% of 
medulloblastoma patients show SHH-pathway activation12,13 and mice with activating 
SHH-pathway mutations develop spontaneous medulloblastomas that recapitulate the human 
disease (14,15). These tumors arise from CGNPs and, like their cells-of-origin, up-regulate 
HK2 and aerobic glycolysis (5,8). CGNP proliferation and SHH-driven tumorigenesis in 
mice typify aerobic glycolysis supporting tumorigenesis arising from developmental growth.
We have previously shown that conditional deletion of Hk2 in the developing brain blocks 
SHH-induced aerobic glycolysis, disrupts CGNP differentiation, and reduces 
medulloblastoma growth, extending the survival of medulloblastoma-prone mice (5). These 
findings demonstrate the importance of aerobic glycolysis in development and cancer, 
suggesting that blocking glycolysis through HK2 inhibition may produce a clinically 
significant anti-tumor effect. Development of selective HK2 inhibitors for anti-cancer 
therapy however, has been problematic (16). Whether targeting glycolysis downstream of 
HK2 would similarly inhibit tumor growth is unknown. To determine whether the distal 
portion of the glycolytic pathway is required for the proliferation of normal and transformed 
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CGNPs, we analyzed the effect of disrupting pyruvate kinase (PK) during cerebellar 
neurogenesis and medulloblastoma formation.
While HK2 initiates glycolysis, PK catalyzes the final step, converting phosphoenolpyruvate 
(PEP) and ADP into pyruvate and ATP (17). Pkm is the pyruvate kinase expressed in the 
brain (18). Alternative splicing of a single exon from Pkm gives rise to either Pkm1, which 
includes exon 9, or Pkm2, where exon 9 replaces exon 10 (19). PKM1 is constitutively 
active and typically expressed in differentiated cells, while PKM2 has a regulated activity 
and is commonly expressed in cancer (20–24). PKM2 can be activated by fructose-1,6-
bisphosphate, an upstream glycolytic intermediate (23,24) and inactivated by interaction 
with tyrosine-phosphorylated proteins responding to growth factor receptor signaling 
(20,21,25). While the regulated activity of PKM2 may allow proliferating cells to adjust 
their metabolism to dynamic requirements (2), the specific benefit of low PKM2 activity has 
not been identified.
PKM2 is expressed in diverse cancers, suggesting a role in cancer growth. Xenograft tumors 
engineered to overexpress either isoform showed that PKM2 expression confers a relative 
growth advantage (26). Other studies have reported non-metabolic, growth-promoting 
functions such as transcriptional regulation (27,28) and histone phosphorylation (29,30). 
However, isoform-specific deletion studies show that PKM2 is not required for tumor 
formation. Aged mice with isoform-specific Pkm2 deletion develop liver cancer (31) and 
breast cancers are accelerated in Brca1-deleted mice with co-deletion of Pkm2 (32). These 
studies identify cancers in which Pkm2 deletion promotes tumor growth. However, neither 
study showed an effect of Pkm2 deletion on tumor glycolysis, potentially because PKM2 
activity may be fully down-regulated in established tumors. To identify metabolic processes 
linking Pkm2 to growth, it is necessary to analyze Pkm2 deletion in normal proliferative 
cells that, unlike cancer cells, are not locked into a proliferative state. CGNPs present an 
ideal opportunity to study Pkm2 function because these cells can modulate both aerobic 
glycolysis and proliferation, and are also vulnerable to malignant transformation in 
medulloblastoma tumorigenesis.
PKM2 is induced by SHH in CGNPs and expressed in the ND2:SmoA1 mouse model of 
medulloblastoma (8), suggesting a role in SHH-driven growth. PKM2 up-regulation has also 
been noted in MYC-amplified Group 3 medulloblastomas (33), suggesting a role for PKM2 
in tumor growth across human medulloblastoma subgroups. Here, we analyzed PKM-
mediated regulation of CGNP glucose metabolism, proliferation, and tumorigenesis. Like 
Hk2 deletion, Pkm2 deletion decreased CGNP conversion of glucose to lactate. However, 
unlike Hk2 deletion, Pkm2 deletion increased SHH-driven proliferation, and accelerated 
medulloblastoma formation in mice expressing a constitutively active Smo allele. The 
differential effects of impeding aerobic glycolysis through deletion of Hk2 or Pkm2 identify 
the glycolytic steps upstream of PK as critical to supporting proliferation during 
development as well as contributing to tumorigenesis.
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Materials and Methods
Animals
All wild-type and genetically engineered mice were maintained on the C57/Bl6 background 
with at least 5 backcrosses. ND2:SmoA1 mice were provided by Dr. James Olson (Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA). Math1-Cre mice were provided by 
Dr. David Rowitch (UCSF, CA, USA) and Robert Wechsler-Reya (Sanford-Burnham 
Medical Research Institute, La Jolla, CA, USA). Eva Anton (UNC-CH, NC, USA) provided 
hGFAP-Cre mice. Pkm2fl/fl mice were generously shared by Dr. Matthew Vander Heiden 
(MIT, Cambridge, MA, USA). Medulloblastoma-prone mice were monitored daily for 
abnormalities of head shape and movement. At the onset of tumor symptoms, such as weight 
loss, ataxia, and impaired movement, animals were sacrificed and survival time to onset of 
symptoms was considered the event-free survival.
For 5-ethynyl-2′-deoxyuridine (EdU) experiments, mice were IP injected with EdU 
(#A10044, Life Technologies, Grand Island, NY, USA) at 40 mg/kg in 50 μL of HBSS and 
dissected 24h later. Brains were fixed in 4% paraformaldehyde in 1X PBS for 24h at 4°C, 
then processed for histology. All animal handling and protocols were carried out in 
accordance with established NIH practices and approved under UNC IACUC #13-121.0 and 
15-306.0.
Cell Culture Techniques
CGNPs were isolated and cultured as previously described (5,34). Briefly, cerebella were 
dissected from P5 pups, dissociated, and allowed to adhere to coated culture wells in 
DMEM/F12 (#11320, Life Technologies, Grand Island, NY, USA) with 25 mM KCl, 
supplemented with FBS and N2. After 4h, media were replaced with identical serum-free 
media. Cells were maintained in 0.5 μg/mL SHH (#464SH, R&D Systems, Minneapolis, 
MN, USA) or vehicle (0.1% BSA in 1X PBS). Where indicated, vismodegib (#S1082, 
Selleck Chemicals, Houston, TX, USA) was added to cultures after the first 24h, at the 
specified concentration, with cells harvested 24h after drug treatment. In vitro CGNP 
proliferation was measured by EdU incorporation after a 1h exposure to 20 μM EdU. EdU 
was visualized following the manufacturer’s protocol (#C10337, Life Technologies). Cell 
counts were performed using Leica-Metamorph software (Molecular Devices, Sunnyvale, 
CA, USA). No cell lines were use in these studies.
In vitro metabolism studies
1H NMR and LC-MS acquisition methods are described in detail in the Supplementary 
Materials and Methods. Briefly, CGNPs of each genotype were cultured in at least 3 
replicate wells. Explanted CGNPs were maintained in [1,6-13C] glucose media for 24h 
followed by media sampling and cell extraction for metabolomic analysis. We normalized to 
cell number at 24 hours to account for differences in growth rates by counting cells in a 
replicate set of wells cultured in parallel.
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For the enzymatic measurement of lactate, media from at least three replicate wells were 
sampled at the specified time points and lactate was quantified using the L-Lactate Assay 
Kit (#1200011002, Eton Bioscience, San Diego, CA, USA) per manufacturer’s protocol.
For PK activity assays, cells from at least three replicate wells per condition, or whole 
cerebella from at least three replicate mice per genotype, were lysed and processed for the 
colorimetric assay per manufacturer’s protocol (#K709-100, BioVision Inc., Milpitas, CA, 
USA).
Histology and immunohistochemistry
Mouse brain and tumor tissues were processed for immunohistochemistry (IHC) as 
previously described35 using antibodies listed in Supplementary Materials and Methods. 
EdU was visualized per manufacturer’s protocol. After IHC and EdU staining, where 
indicated, nuclei were counterstained with 200 ng/mL 4′6-diamidino-2-phenylindole (DAPI; 
#D1306, ThermoFisher Scientific, Waltham, MA, USA) in 1X PBS for 5 min. Stained slides 
were digitally acquired using an Aperio ScanScope XT (Aperio, Vista, CA, USA). Where 
indicated, maximum intensity projections of stained tissue sections were acquired on a Zeiss 
LSM 780 confocal microscope with a Plan-Apochromat 20× objective (NA 0.8). To quantify 
EdU, Proliferating Cell Nuclear Antigen (PCNA), and p27Kip1 positive cells in the EGL, the 
EGL region was manually annotated on each section, which was then subjected to 
automated cell counting using Tissue Studio (Definiens, München, Germany) for fluorescent 
slides. For premalignant lesion analysis, the entire cerebellum was annotated and used for 
cell counts.
Western blot analysis
Cultured cells and whole cerebella were lysed by homogenization in RIPA buffer containing 
protease inhibitor cocktail, NaF, and sodium orthovanadate. Protein concentrations were 
quantified using the bicinchoninic acid (BCA) method (#23229, ThermoFisher Scientific) 
and equal concentrations of protein were resolved on SDS-polyacrylamide gels followed by 
transfer onto polyvinylidene difluoride membranes. Immunologic analysis was performed on 
the SNAP i.d. Protein Detection System (Millipore, Billerica, MA, USA) per manufacturer’s 
protocol with antibodies listed in Supplementary.
Materials and Methods—Western blots were developed using the enhanced 
chemiluminescent SuperSignal West Femto Maximum Sensitivity Substrate (#34095, 
ThermoFisher Scientific) and digitized using the C-DiGit blot scanner (LI-COR, Lincoln, 
NE, USA). Quantification was performed using Image Studio Lite software (LI-COR).
DNA sequencing
DNA was lysed from toe cuttings and used to generate Pkm2 PCR products. Pkm2 PCR 
primers were F_TAGGGCAGGACCAAAGGATTCCCT and 
R_CTGGCCCAGAGCCACTCACTCTTG. PCR products were extracted from a 0.8% 
agarose gel using the MinElute Gel Extraction Kit (#28604, Qiagen, Valencia, CA, USA), 
cloned by TOPO TA Cloning (#K4575-J10, Life Technologies) and sequenced from the 
M13F and M13R primer sites by Sanger sequencing (Eton Bioscience).
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Patients and samples
All patient samples were obtained with consent as outlined by individual institutional review 
boards. Written informed consent was obtained at the time of surgical resection. De-
identified medulloblastoma tissues were obtained from Queensland Children’s Tumor Bank 
(Brisbane, Australia), German Cancer Research Center (Heidelberg, Germany), Sanford-
Burnham Medical Research Institute (La Jolla, USA), and Hospital for Sick Children 
(Toronto, Canada).
Differential Pkm isoform expression analysis of RNA-seq data
Library construction, sequencing, and alignment of RNA-seq data are described in detail in 
the Supplementary Materials and Methods. Transcriptome aligned binary alignment files 
(bams) were processed using RNA-Seq by Expectation Maximization (RSEM) software 
(36). The reference for RSEM was built using the same GRCh37-lite assembly and 
GRCh37.75 GTF as used by STAR aligner (37). This was followed by the calculation of 
PKM isoform level FPKM using RSEM with default parameters in 97 human tumors. The 
accession number for the RNA-seq data is European Genome-phenome Archive: 
EGAD00001001899.
Survival analysis of SHH-subgroup medulloblastoma patients
PKM2 FPKM expression was converted to a Z-score and used to segregate SHH patients 
into a high or low category with the criteria of being greater than 0.5 or smaller than −0.5 
respectively. A cox proportional hazard model was used to determine the presence of a 
survival difference.
Results
Pkm isoform expression in the brain mirrors differentiation status
We found dichotomous Pkm isoform expression in the postnatal brain that varied with 
differentiation state. was in Differentiated neurons throughout the brain expressed PKM1 
and not PKM2 (Fig. 1A). In contrast, neural progenitors of the cerebellar external granule 
layer (EGL), hippocampus (HC), and subventricular zone/rostral migratory stream (SVZ/
RMS) expressed PKM2 and not PKM1 (Fig. 1B).
The temporal expression of PKM2 in the cerebellum coincided with postnatal neurogenesis. 
CGNP proliferation peaks at postnatal day 7 (P7) and ends by P15, as CGNPs progressively 
exit the cell cycle, migrate to the internal granule layer (IGL), and differentiate into 
cerebellar granule neurons (CGNs) (3,4,7). Western blot of whole cerebellum lysates 
showed that PKM2, like the CGNP proliferation marker Cyclin-D2 (CCND2), decreased 
between P7 and P15, while PKM1 conversely increased (Fig. 1C). PKM2 was not limited to 
proliferating progenitors; both proliferating, PCNA+ CGNPs in the outer layer of the EGL 
(oEGL), and differentiating, PCNA− CGNPs of the inner EGL (iEGL) expressed PKM2 
(Fig. 1D). Similarly, in the SVZ/RMS, both PCNA+ and PCNA- progenitors expressed 
PKM2 (Fig. 1E). Thus, PKM2 marked undifferentiated brain progenitors, whether 
proliferating or quiescent, while PKM1 marked differentiated neurons.
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To determine if medulloblastomas, like CGNPs, exclusively expressed PKM2, we analyzed 
PKM isoform expression in transgenic, medulloblastoma-prone ND2:SmoA1 mice. 
ND2:SmoA1 mice express a mutant, constitutively active allele of Smo, driven by the 
NeuroD2 promoter. In CGNPs of ND2:SmoA1 mice, SHH-pathway activation prolongs 
proliferation beyond P15. These mice develop medulloblastoma with incomplete penetrance 
after a variable latency (14). During this latent period, CGNPs continue to proliferate in 
premalignant lesions within the EGL, generating progeny that differentiate, undergo 
apoptosis, or remain proliferative.
We found that CGNPs in premalignant lesions of P60 ND2:SmoA1 mice expressed PKM2 
and not PKM1 (Fig. 1F). Similarly, medulloblastomas derived from these premalignant 
lesions consistently and homogeneously expressed PKM2, while adjacent, normal brain 
expressed PKM1 (Fig. 1G). We compared the expression of PKM1 and PKM2 mRNA in 
human medulloblastoma samples by RNA-seq. As in the mouse model, we found exclusive 
expression of PKM2, with minimal PKM1 in all four medulloblastoma subgroups (Fig. 1H). 
Together, our studies of mouse and human tumors show that developmental PKM2 
expression persists throughout medulloblastoma tumorigenesis.
SHH stimulates PKM2 expression
To examine the effect of SHH signaling on PKM1/2 expression, we isolated CGNPs and 
compared PKM isoform expression in the presence or absence of SHH ligand. We labeled S-
phase cells by adding EdU to CGNP cultures 1h before fixation. EdU+ and PKM2+ cells 
were more numerous in SHH-treated wells (Fig. 2A; cyan arrows) compared to SHH-
deprived controls (Fig. 2B; arrows). In SHH-treated wells, PKM2 was detected in both EdU
+ and EdU− cells (Figs. 2A,B; white arrowheads). Consistent with the absence of PKM1 in 
the EGL, no CGNPs in either condition showed detectable PKM1; rare cells that were 
PKM1+ did not have morphology characteristic of CGNPs (Figs. 2C,D). These data show 
that SHH sustained PKM2 expression in CGNPs, while PKM1 expression remained low 
during the initiation of differentiation in SHH-deprived CGNPs.
To determine the effect of SHH inhibition on PKM expression, we analyzed SHH-treated 
CGNPs exposed to the Smo inhibitor vismodegib (38) by quantitative PKM Western blot. As 
an indicator of SHH-driven proliferation, we also measured CCND2 expression. SHH-
treated CGNP explants demonstrated 5.5-fold more CCND2 compared to SHH-deprived 
CGNPs, and 2-fold more PKM2 (Fig. 2E). PKM1, which likely originated from rare cells 
detected by IHC (Figs. 2C,D) was also significantly increased SHH-treated explants. 
Vismodegib decreased CCND2 by 30% but did not significantly alter PKM1 or PKM2 
expression (Fig. 2E). Thus, both PKM2 and CCND2 were up-regulated by SHH, but 
compared to CcnD2, Pkm was markedly less responsive to changes in SHH signaling. These 
data suggest that Pkm, unlike CcnD2 (11), is not a direct SHH target.
PK activity in CGNPs is increased by growth stimulation
Tyrosine kinase signaling, and specifically insulin signaling, can down-regulate PKM2 
catalytic activity in diverse cell lines (21,39,40). While CGNPs are typically cultured with 
insulin-rich N2 supplement to improve cell viability (41), we have shown that CGNPs can 
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be cultured without N2 for 24h, reducing IGFR activation without compromising survival 
(5). We maintained CGNPs in the presence or absence of SHH or N2, to determine the effect 
of SHH/IGFR co-stimulation on Pkm expression and PK activity in CGNPs.
We found that SHH/IGFR co-stimulation was required for CGNP aerobic glycolysis, as N2 
deprivation reduced lactate production (Fig. 2F) in a manner comparable to SHH-
withdrawal5. We have shown that growth factor stimulation induces aerobic glycolysis 
through a complex program that depends on many genes, including N-myc and Hk2 (5). To 
determine if this program may include changes in PK activity and PKM expression, we 
analyzed CGNPs cultured with or without SHH or N2. N2-deprivation potently inhibited 
IGF signaling, resulting in a 70% reduction in AKT phosphorylation, and more modestly 
reduced PKM2 expression by 30% (Supplementary Fig. S1). By measuring the conversion 
of exogenous PEP to pyruvate in CGNP lysates, we found that CGNPs maintained with 
SHH+N2 showed significantly higher PK activity compared to either SHH without N2 or N2 
without SHH (Figs. 2G,H). These findings show that CGNP PK activity and PKM2 
expression were responsive to extracellular signaling, and were maximal with SHH/IGFR 
co-activation, thus varying directly with glycolysis. While reduced PK activity has been 
correlated with growth factor stimulation in cancer cells (20,25,26), in CGNPs, 
developmentally-relevant growth factors increased PKM2 expression, PK activity, and 
aerobic glycolysis.
Pkm2 deletion is not replaced by Pkm1 in brain progenitors
To determine the developmental significance of PKM in CGNPs, we examined the effect of 
conditionally deleting the Pkm2-specific exon 10 (19). We crossed Math1-Cre mice, which 
express Cre recombinase in CGNPs (42,43), with Pkm2fl mice that harbor loxP sites 
flanking Pkm exon 1032. The resulting Math1-Cre;Pkm2fl/fl mice (Pkm2cKO) mice were 
viable and fertile without neurologic deficits. Pkm2cKO cerebellum showed normal foliation 
and cellular organization, without PKM2 or PKM1 in the EGL (Fig. 3A,B). PKM1 
expression was increased in IGL of Pkm2cKO mice, which is populated by CGNs that derive 
from CGNPs and inherit the deletion of exon 10 (Fig. 3A). Thus, Pkm2 deletion in the 
Math1 lineage did not induce compensatory PKM1 in progenitors but did increase PKM1 
expression by terminally differentiated neurons. Consistent with these changes, Western blot 
showed reduced PKM2 and increased PKM1 in P7 Pkm2cKO cerebella compared to no-Cre 
littermate controls (Fig. 3C). In whole cerebellum lysates, PK activity was equivalent in 
Pkm2cKO and littermate controls (Fig. 3D). In CGNPs, however, Pkm2 deletion blocked all 
detectable PKM expression.
During the breeding of Pkm2cKO mice, we noted an unanticipated tendency for germline 
recombination of the Pkm2fl allele. This recombination event was detected as a smaller-
than-expected PCR product when primers flanking Pkm exon 10 were used to amplify 
genomic DNA. While these primers were separated by 605 bp in the Pkm2fl/fl allele and 560 
bp in the Pkm2+/+ allele, we found pups in several litters that generated 220 bp PCR 
products consistent with the recombined allele (Supplementary Fig. S2A). Sequencing of 
this band demonstrated that intron 9–10 and 10–11 were brought together, separated by a 
single loxP site, consistent with Cre-mediated excision of exon 10 from Pkm (32) 
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(Supplementary Fig. S2B). Similar germline recombination has been observed when Pkm2fl 
mice were crossed with other non-germline Cre drivers (M. Vander Heiden, unpublished), 
suggesting that Pkm exon 10 deletion is positively selected in the germline. The recombined 
allele (Pkm2null) was heritable and Pkm2null/null mice were viable and fertile without 
neurologic abnormalities, consistent with the published Pkm2 null phenotype (31). Pkm2 
null mice have been reported to develop spontaneous hepatocellular carcinoma in the second 
year of life (31), however, we did not observe any spontaneous tumor formation in our 
Pkm2null/null aged up to one year. In Pkm2null/null mice, PKM2 was absent from all brain 
cells, while PKM1 was appropriately limited to differentiated neurons (Supplementary Fig. 
S2C,D). Like Pkm2cKO mice, Pkm2null/null mice showed normal brain anatomy.
Pkm2 deletion increases CGNP proliferation
Although Pkm2cKO cerebella had normal organization, quantitative analysis showed that 
CGNP proliferation was increased compared to PKM2-intact littermate controls. We 
analyzed proliferation dynamics in vivo, by injecting EdU at P6 into Pkm2cKO and Pkm2fl/fl 
no-Cre littermates. We harvested cerebella 24h after EdU injection and quantified the 
number of EdU+ cells in the EGL that expressed the CGNP differentiation marker p27Kip1. 
Both genotypes included differentiating, EdU+p27 Kip1+ CGNPs and proliferating, EdU
+p27Kip1−CGNPs (Figs. 4A,B). While EdU labeling was similar between genotypes (Fig. 
4C), we noted a trend toward reduced p27Kip1 labeling in Pkm2cKO CGNPs (Fig. 4D). 
Importantly, EdU+ CGNPs that were p27Kip1- were more numerous in the EGL of Pkm2cKO 
mice (Fig. 4E). In vitro studies provided additional evidence of increased proliferation with 
Pkm2 deletion, as CGNPs explanted from Pkm2cKO mice showed a higher fraction of EdU+ 
cells after a 1h pulse, compared to CGNPs explanted from littermate controls (Fig. 4F).
Consistent with increased proliferation of Pkm2cKO CGNPs, analysis of equivalent midline 
cerebellar sections showed that Pkm2cKO cerebella contained significantly more cells 
(CGNPs and CGNs) compared to littermate controls (Fig. 4G). The ratio of EGL:IGL was 
not significantly different between genotypes however (Fig. 4H), indicating that Pkm2 
deletion did not prevent CGNPs from progressing through their normal differentiation 
trajectory. Thus, Pkm2 deletion blocks all PKM expression in CGNPs, with the effects of 
increasing proliferation and reducing cell cycle exit, without altering cell fate.
Pkm2 deletion inhibits the catabolism of glucose to lactate
We used a non-biased, metabolomic approach to determine the effect of Pkm2 deletion and 
consequent loss of PKM function on CGNP metabolism. We isolated CGNPs from P5 
Pkm2cKO mice and littermate controls and cultured them in three replicate wells for 24h in 
media with [1,6-13C] glucose replacing unlabeled glucose. We analyzed media metabolites 
from each replicate well for each condition at 0 and 24h using NMR spectroscopy followed 
by orthogonal partial least squares discriminant analysis to identify species with metabolic 
rates that varied consistently across genotypes (Supplementary Table S1).
Lactate production was significantly reduced in Pkm2cKO CGNPs compared to controls 
(Fig. 5A). Lactate was the species with the largest change in metabolic rate in Pkm2cKO 
CGNPs versus controls (Supplementary Table S1). Lactate production and arginine 
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utilization were both significantly reduced in the Pkm2-deleted cells, but the change in 
arginine was 10-fold smaller and unlikely to be directly related to glucose metabolism. We 
confirmed that Pkm2cKO CGNPs produced less lactate by measuring media lactate in 
replicate wells by colorimetric assay (Fig. 5B). The 13C fractional enrichment of lactate was 
also decreased in Pkm2cKO CGNPs (Figs. 5C,D), showing that a smaller proportion of 
utilized glucose was converted to lactate.
To determine how Pkm2 deletion altered the intracellular disposition of glucose in CGNPs, 
we analyzed cell extracts by liquid chromatography-mass spectrometry (LC-MS). Diverse 
molecules detected by LC-MS detected did not show significantly different distribution 
between genotypes. We noted a trend toward increased choline in Pkm2cKO CGNPs; this 
trend cannot be directly related to glucose metabolism, but is consistent with increased 
proliferation (Fig. 5E). We were able to detect 13C-labeling in glutamate, which we used as a 
measure of flow through the Krebs cycle, and in the ribose component of ATP, ADP and 
AMP, which we used as a measure of flow through the pentose phosphate pathway (PPP) 
(Fig. 6).
Relative to Pkm2-intact controls, Pkm2cKO CGNPs showed a small, but statistically 
significant decrease in glutamate with 3 or 4 13C atoms (Fig. 6). The incorporation of 
multiple 13C atoms from [1,6-13C] glucose requires both conversion of pyruvate to acetyl-
CoA by PDH and multiple turns of the Krebs cycle (Supplementary Fig. S3). The reduced 
glutamate with 3 or 4 13C atoms in controls indicates that that PKM2 deletion marginally 
reduced labeling downstream of PDH, consistent with a shift in fate of glucose-derived 
carbons.
Both genotypes demonstrated 13C incorporation into ribose. LC-MS demonstrated labeled 
parent masses of ATP, ADP, and AMP that fragmented into unlabeled adenine and 13C-
labeled ribose. These data demonstrate active flow through the PPP. However, we did not 
detect a robust difference in PPP flux between genotypes (Fig. 6). These data suggest that 
unidentified reactions in Pkm2cKO CGNPs bypass the conversion of PEP to pyruvate, 
allowing the incorporation of 13C into glutamate and lactate at a reduced but detectable rate, 
while maintaining comparable flow through the PPP. In net, Pkm2 deletion redirected 
glucose-derived metabolites away from both lactate generation and retention in the Krebs 
cycle, without causing a large increase in PPP flux.
Medulloblastoma tumorigenesis is exacerbated by loss of PKM2
We examined the functional consequence of Pkm2 deletion on SHH-driven medulloblastoma 
tumorigenesis by crossing Pkm2cKO and Pkm2null/null mice with medulloblastoma-prone 
mouse lines. We generated tumor-prone mice using either the SmoM2 allele that induces 
rapidly developing progressive medulloblastoma with 100% incidence by P20, or with the 
ND2:SmoA1 allele that induces tumors more slowly. In contrast to the anti-tumor effect of 
Hk2 deletion, we found that Pkm2 deletion did not slow tumor progression in Math1-
Cre;SmoM2;Pkm2fl/null mice (Fig. 7A) or hGFAP-cre;SmoM2;Pkm2fl/null mice (data not 
shown) compared to Pkm2-intact, littermate controls. In both of these models, however, 
rapid tumor growth limits the ability to determine whether PKM2 ablation accelerates 
disease. To address this question, we examined Pkm2 deletion in ND2:SmoA1 mice.
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ND2:SmoA1 mice with Pkm2 deletion developed tumors more frequently than Pkm2-intact 
ND2:SmoA1 controls. We compared ND2:SmoA1 mice with two mutant copies of Pkm2, 
including Math1-Cre;ND2:SmoA1;Pkm2fl/fl, Math1-Cre;ND2:SmoA1;Pkm2fl/null, and 
ND2:SmoA1;Pkm2null/null genotypes to control ND2:SmoA1 mice with two intact copies of 
Pkm2, including no-Cre;ND2:SmoA1;Pkm2+/+, no-Cre;ND2:SmoA1;Pkm2fl/+, and Math1-
Cre;ND2:SmoA1;Pkm2+/+ genotypes. We observed a trend toward increased tumor 
formation in Pkm2–deleted mice at P150, where the incidence was 37.5% with Pkm2 
deletion vs 15.8% for controls (p=0.245, Fisher’s Exact test). By 300, tumor incidence was 
100% in Pkm2-deleted mice versus 57.9% for controls (p=0.004, Fisher’s Exact test). 
Consistently, ND2:SmoA1 mice with Pkm2 deletion demonstrated significantly shorter 
progression-free survival (Fig. 7B).
To determine if Pkm2 deletion accelerated tumor growth through a cell autonomous process, 
we separately compared the Math1-Cre;ND2:SmoA1;Pkm2fl/null and 
ND2:SmoA1;Pkm2null/null subgroups to Pkm2-intact ND2:SmoA1 controls. This analysis 
also showed significantly shorter survival for both Math1-Cre;ND2:SmoA1;Pkm2fl/null (Fig. 
7C) and ND2:SmoA1;Pkm2null/null genotypes (Fig. 7D). We found no statistically 
significant difference between different Pkm2-deleted genotypes. Thus, the accelerating 
effect of Pkm2 deletion on SmoA1-driven tumorigenesis was cell autonomous.
Like Pkm2-deleted CGNPs, Pkm2-deleted medulloblastoma cells expressed neither PKM2 
(Fig. 7E) or PKM1 (Fig. 7F). However, we noted scattered PKM1+ cells within Pkm2-
deleted tumors (Fig. 7E’”). These cells were consistently PCNA- (Supplementary Fig. S4) 
and were also found in Pkm2-intact tumors. These non-proliferative, PKM1+ cells may be 
entrapped neurons or differentiated progeny of tumor cells. Similar PKM1+ stromal cells 
were previously observed in Pkm2-deleted breast tumors (32).
The slow process of tumor formation in ND2:SmoA1 mice allowed us to analyze the effect 
of Pkm2 deletion on the growth of premalignant lesions. We counted PCNA+ cells in 
cerebella of ND2:SmoA1 mice with deleted or intact Pkm2, harvested at either P60 or P120 
and normalized the number of PCNA+ cells to the total number of cells in each cerebellar 
section (Fig. 7G). In controls, the median fraction of PCNA+ cells in the cerebellum and the 
range of these values decreased over time, consistent with a dynamic balance between 
growth and growth suppression. In contrast, in Pkm2-deleted genotypes, the median and 
range of PCNA+ fractions increased over time, consistent with reduced growth suppression 
during the premalignant period. Altogether, Pkm2 deletion increased SHH-driven CGNP 
proliferation during development, accelerated tumorigenesis in premalignant lesions in Smo-
mutant mice, and increased the incidence of tumor formation from these lesions.
The more rapid progression of mouse tumors with Pkm2 deletion was mirrored by a trend 
toward shorter survival in medulloblastoma patients with low PKM2 expression. We 
classified SHH-subgroup medulloblastoma patients as having either high or low PKM2 
expressing tumors and compared their clinical outcomes. All patients were treated similarly 
with radiation and chemotherapy. While not statistically significant, we found that patients 
with low PKM2 expression trended toward shorter survival times (Fig. 7H). Together, these 
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data confirm that PKM2 is not essential for tumor progression and suggest that low PKM2 
expression, like Pkm2 deletion, enhances medulloblastoma tumor growth.
Discussion
We analyzed the functional significance of pyruvate kinase isoform expression in the 
developing brain and in medulloblastoma. While aerobic glycolysis has been associated with 
proliferation in both development (5,44) and cancer (1,2), our data show that disrupting 
glycolysis at PK increases, rather than decreases both developmental proliferation and 
tumorigenesis. We show that within the neural lineage, Pkm is spliced into mutually 
exclusive expression patterns that correlate PK activity with differentiation state. In the 
postnatal brain, undifferentiated progenitors in the cerebellum, hippocampus, and SVZ 
expressed the less active PKM2 isoform, while differentiated neurons expressed the more 
active PKM1. The correlation of PKM2 with the undifferentiated state was maintained in 
medulloblastoma. The PKM1:PKM2 dichotomy persisted after conditional or germline 
deletion of Pkm2, which increased PKM1 in differentiated cells but not in progenitors. The 
lack of compensatory up-regulation of PKM1 in brain progenitors contrasts with prior 
observations in MEFs and other tissues, where PKM1 expression increases on Pkm exon 10 
deletion (31,45). In Pkm2-deleted MEFs, increased PKM1 caused nucleotide scarcity and 
cell cycle arrest. However, Pkm2cKO CGNPs expressed neither PKM isoform, showed 
decreased conversion of glucose to lactate and increased proliferation. Pkm2 deletion also 
enhanced the growth of premalignant lesions and tumors in ND2:SmoA1 mice. These 
findings demonstrate that the absence of detectable PKM2 in Pkm2cKO mice increased 
developmental proliferation and neural progenitor susceptibility to tumorigenesis.
The different effects of Pkm2 deletion in CGNPs and MEFs argue that proliferation is 
restricted by PKM1, rather than enhanced by PKM2. We propose that high PK activity 
inhibits SHH-driven proliferation and suppresses tumor formation. Consistent with this 
model, splicing Pkm to PKM2 has a permissive effect on proliferation and abrogating PKM 
expression is more permissive. The finding that SHH/IGFR co-signaling increased CGNP 
PK activity is not necessarily inconsistent with this model as growth factors are known to 
induce simultaneously both positive and negative regulation of proliferation in primary cells. 
For example, SHH activation induces Patched (Ptc) expression in CGNPs, which negatively 
regulates SHH signaling (46,47). Activating PKM2 may be a similar inhibitory element 
within the normal regulation of SHH-induced growth in primary cells.
Our prior Hk2 deletion studies demonstrate that the initiation of glycolysis supports 
postnatal neurogenesis and sustains the malignant growth of medulloblastomas. In contrast, 
our present studies of Pkm2 deletion show that impeding the flow of glucose to lactate 
increases CGNP proliferation and accelerates medulloblastoma tumorigenesis. Together, 
these deletion studies show that the pathways through which glucose is metabolized 
significantly influence the proliferative behavior of undifferentiated cells. The divergent 
effects of Hk2 deletion versus Pkm2 deletion establish the glycolytic steps upstream of PK 
as critical to supporting the proliferative phenotype of neural progenitors and cognate 
tumors.
Tech et al. Page 12
Cancer Res. Author manuscript; available in PMC 2018 June 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Between the reactions catalyzed by HK2 and PKM2 are several reversible reactions that 
permit glycolytic intermediates to be shunted toward biosynthetic processes. We and others 
have previously proposed that low flow downstream of PEP, achieved by preferentially 
splicing PKM to generate PKM2, may support growth by diverting glycolytic intermediates 
away from lactate generation and towards the synthesis of macromolecules (2,48,49). 
However, evidence for decreased lactate and increased anabolism with Pkm2 deletion was 
lacking in Pkm2-deleted breast tumors (32) and MEFs (45). Recent work found that the 
direct incorporation of glucose carbons is a minor component of the biomass of proliferating 
cancer cells (50). Working with primary neural progenitors limited the amount of material 
for analysis and thus the range of metabolites we could detect. However, we were able to 
detect 13C in extracellular lactate and in intracellular glutamate and ribose. Pkm2 deletion 
decreased the incorporation of glucose into lactate and glutamate, suggesting that that 
altering PEP metabolism redirects glucose carbons to different metabolic fates. Pkm2 
deletion did not produce a detectable effect on the incorporation of glucose into ribose, 
suggesting that PPP flux is not the major destination of glucose carbons redirected by low 
PK activity.
Our 13C studies show that CGNPs lacking both PKM1 and PKM2 can metabolize glucose to 
pyruvate, raising the question of what alternative pathway metabolizes PEP. We were not 
able to detect changes in glycolytic intermediates that might indicate how PEP is processed 
in Pkm2cKO CGNPs. However, prior studies have shown that PKM2-expressing cells with 
low PK activity can generate pyruvate by transferring the high-energy phosphate of PEP to 
the enzyme PGAM1(51). This phosphorylation activates PGAM1, which may promote 
biosynthetic metabolism (52). If PEP-PGAM1 phosphotransfer occurs in CGNPs, it may 
mediate the growth promoting effect of PKM2 splicing that is enhanced by Pkm2 deletion.
Our work suggests that Pkm functions as a tumor suppressor. Identifying Pkm as a tumor 
suppressor has profound implications for aerobic glycolysis and may be effectively targeted 
in cancer treatment. Inhibiting PKM function as an anti-cancer therapy would be 
counterproductive while drugs that increase PKM catalytic activity may be of limited 
therapeutic value if tumors can thrive with low PKM expression. The loss of tumor 
suppressor genes, however, may be targeted through alternative approaches that require 
defining the consequent changes in pathway regulation (53,54). A detailed understanding of 
how low PK activity promotes proliferation may produce novel clinical strategies to treat 
tumor growth.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PKM1 and PKM2 correspond to differentiation state
IHC (brown) shows (A–A″) PKM1 in differentiated neurons throughout the brain and (B–B
″) PKM2 in neural progenitors of the SVZ, HC, and EGL. (C) Western blot of CCND2, 
PKM2, and PKM1 in whole cerebellum lysates harvested at the indicated age, normalized to 
β-actin. PKM2 decreases from P7 (n=4) to P15 (n=4), while PKM1 increases. Graph 
presents mean±s.e.m. Immunofluorescence shows PKM2 in (D) the PCNA+ oEGL and the 
PCNA− iEGL of in P7 wildtype mice and (E) PKM2 in PCNA+ and PCNA− (arrowheads) 
SVZ progenitors. (F) Premalignant lesions in P60 ND2:SmoA1 mice identified by PCNA, 
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are PKM2+ and PKM1−. (G) PKM2 and PCNA are expressed in a ND2:SmoA1 
medulloblastoma; adjacent normal tissue expresses PKM1. (H) RNA-seq shows preferential 
expression of PKM2 in all human medulloblastoma subgroups. P-values determined by 
Student’s t-tests. High magnification of boxed areas shown on the right. PC=Purkinje cell 
layer; ML=molecular layer; FPKM=Fragments Per Kilobase of transcript per Million 
mapped reads. Scale bars: 2 mm (A,B,G); 600 μm (A′,B′); 100 μm (A″,B″,E); 50 μm (D,E 
inset); 1 mm (F); 500 μm (F′–F‴); 300 μm (G′–G‴).
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Figure 2. Growth factor signaling regulates PKM expression and activity
(A,B) PKM2 immunofluorescence on explanted CGNPs exposed to EdU for 1h, +/− SHH. 
(C,D) Rare cells within CGNP explants expressed PKM1 (arrowheads) in both SHH-treated 
and vehicle-treated wells. (E) Quantitative Western blot of CCND2, PKM2, and PKM1 in 
cell cultures, normalized to β-actin (n=4/condition). (F) N2-deprived CGNPs produce less 
lactate detected by enzymatic assay (n=3/condition). (G,H) CGNP PK activity increases 
with combined SHH and N2 supplementation (n=3/condition). Graphs present mean±s.e.m. 
P-values determined by Student’s t-tests. Scale bars: 50μm.
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Figure 3. Pkm2 deletion blocks all PKM expression in CGNPs
(A,B) IHC shows PKM1 and PKM2 in representative sagittal cerebellar sections from P7 
Ctrl and Pkm2cKO mice. Pkm2 deletion does not induce compensatory PKM1 expression in 
the EGL. High magnification of boxed area is shown on the right. (C) Quantitative Western 
blot normalized to β-actin in whole P7 cerebellum lysates demonstrates decreased PKM2 
and increased PKM1 (n=4/condition). (D) PK activity in whole P7 cerebellum lysates is 
similar between genotypes. Graphs present mean±s.e.m. P-values determined by Student’s t-
tests. Scale bars: 500μm; 100μm (insets).
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Figure 4. Pkm2 deletion increases CGNP proliferation
(A,B) Representative confocal images of P7 Ctrl and Pkm2cKO cerebellar sections labeled 
for the p27Kip1 and for EdU, 24h after EdU injection (n=3/condition). High magnifications 
of boxed areas are shown on the right. (C,D) Quantification of EdU+ cells and p27Kip1+ 
cells in the EGL. (E) The p27Kip1− fraction of the EdU+ population is significantly larger in 
the Pkm2cKO EGL, indicating increased cell cycle re-entry. (F) Comparison EdU 
incorporation by CGNPs of indicated genotype, cultured with SHH and exposed to EdU for 
1h. (G,H) Analysis of midsagittal cerebellar sections shows increased EGL and IGL 
populations in Pkm2cKO mice (n=5) versus controls (n=4), with preserved EGL:IGL ratio. 
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Graphs present mean±s.e.m. P-values determined by Student’s t-tests. Scale bars: 500μm; 
50μm (insets).
Tech et al. Page 22
Cancer Res. Author manuscript; available in PMC 2018 June 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. Pkm2 deletion reduces lactate production
(A) 1H NMR analysis of media sampled after 24h of culture demonstrates decreased lactate 
in Pkm2cKO wells (n=4) compared to controls (n=3) (**p=0.029). (B) Comparison of media 
lactate between genotypes, measured by enzymatic assay. (C) Representative 1H NMR 
spectra of Ctrl and Pkm2cKO 24h media demonstrate the peaks representing [3-13C] lactate 
(dashed line) and unlabeled lactate (solid line). (D) Quantification of 13C-enriched fraction 
of lactate, from samples in (A). (E) LC-MS analysis of indicated metabolites in CGNP 
extracts, comparing genotypes. Graphs present mean±s.e.m. P-values determined by 
Student’s t-tests. FE=fractional enrichment.
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Figure 6. Pkm2-deleted CGNPs show altered glutamate progression through the Krebs cycle but 
comparable PPP flux
Comparison between SHH-treated CGNPs of indicated genotypes cultured for 24h with 
[1,6-13C] glucose, showing 13C labeling of ribose-labeled adenine nucleotides, and 
glutamate (mean±s.e.m). The diagram is provided to show how 13C glucose carbons 
accumulate in ribose and glutamate. P-values determined by Student’s t-tests. 
OxPPP=oxidative phase of pentose phosphate pathway; Non-OxPPP=non-oxidative phase of 
pentose phosphate pathway; GAP=glyceraldehyde-3-phosphate; X5P=xylulose-5-phosphate; 
E4P=erythrose-4-phosphate; F6P=fructose-6-phosphate; S7P=Sedoheptulose-7-phosphate; 
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R5P=ribose-5-phosphate; Ru5P=ribulose-5-phosphate; LDH=lactate dehydrogenase; 
PDH=pyruvate dehydrogenase; PC=pyruvate carboxylase.
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Figure 7. Pkm2 deletion accelerates medulloblastoma tumorigenesis
(A–D) Kaplan-Meier curves demonstrate the effect of Pkm2 deletion on survival in (A) the 
rapidly progressive Math1-Cre;SmoM2 model and (B) the slow-growing ND2:SmoA1 
model, including (C) ND2:SmoA1 mice with (C) conditional or (D) global Pkm2 deletion. 
(E,F) A representative P147 Pkm2-deleted ND2:SmoA1 medulloblastoma shows (E–E‴) 
PKM1 (brown) in normal brain and (F–F‴) absence of PKM2 (brown). (G) Comparison of 
premalignant lesions at P60 and P120 between genotypes. The proportion of PCNA+/total 
cells in the cerebellum increases over time in the Pkm2-deleted genotypes. (H) Kaplan-
Meier curve demonstrates a trend toward shorter survival in SHH medulloblastoma patients 
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with low PKM2 expression. P-values determined by log-rank test (A–D), cox proportional 
hazard model (H), and by Student’s t-test (G). Scale bars: 2mm (E,F); 100μm (E′-E‴,F′-F
‴).
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